Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study
Crossref DOI link: https://doi.org/10.1007/s00228-016-2104-3
Published Online: 2016-07-29
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Boucaud-Maitre, Denis
Altman, Jean-Jacques
License valid from 2016-07-29
